News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Independent Research Demonstrates Ability of Vicor Technologies, Inc.' PD2i(R) Nonlinear Algorithm to Identify a Wide Array of Medical Conditions and Disorders


5/4/2011 8:28:05 AM

BOCA RATON, FL--(Marketwire - May 04, 2011) - David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the Company has identified 45 published manuscripts detailing independent studies involving the use of its PD2i® nonlinear algorithm to identify a wide variety of medical disorders and conditions. This brings the total number of published manuscripts of studies involving Vicor's PD2i® nonlinear algorithm to 60. Vicor Technologies is a biotechnology company focused on the commercialization of its PD2i Analyzer™, an innovative, non-invasive diagnostic employing its patented, proprietary PD2i® nonlinear algorithm. Physician use of the PD2i Analyzer™ is supported by an expanding body of literature documenting the PD2i® nonlinear algorithm as a metric for risk stratifying specific target populations for future pathological events, including diabetics for the presence of diabetic autonomic neuropathy (DAN), cardiovascular disease patients for death resulting from arrhythmia or congestive heart failure, and trauma victims for imminent death absent immediate lifesaving intervention.

These independent studies, which are not for FDA-approved indications, include the use of Vicor's PD2i® nonlinear algorithm to:

  • predict seizure, transplant rejection, and ventricular fibrillation;
  • identify stress, depression, sleep apnea, autoimmune system imbalance, increased neural complexity in schizophrenic patients, impact of ECT therapy on depression, and the effect of estrogen and testosterone on convergent and divergent thinking; and
  • locate seizure focus for epileptic surgery.

"While the scientific community recognizes that heart rate variability is a useful measure of the health of many bodily functions, the issue for using heart rate variability as a diagnostic in the clinical setting has been thwarted by accuracy issues. As these independent studies attest, Vicor's PD2i® nonlinear algorithm has successfully demonstrated the ability to accurately measure heart rate variability to predict and identify a variety of medical conditions and disorders. We are excited by the range of human conditions and disorders that can be identified early in their arc and thereby provide physicians with the ability to enhance patient treatment and outcomes. We look forward to continuing clinical studies in a variety of areas -- chief among these, sudden cardiac death and head trauma in athletes -- to establish the Analyzer™ as a widely used diagnostic in the clinical setting," stated Mr. Fater.

About VicorTechnologies, Inc.
Vicor Technologies' PD2i Analyzer™ employs its patented, proprietary point correlation dimension algorithm (PD2i®), a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations. Vicor anticipates use of its PD2i Analyzer™ to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Caution Regarding Forward-Looking Statements
Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to successfully complete the normal range study for PD2i® values; our ability to generate revenues from the sale of the PD2i Analyzer™; our ability to obtain the necessary regulatory approvals to market the PD2i Analyzer™; our ability to develop additional applications for the PD2i Analyzer™; the ability of additional sales representatives to create revenue; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor's Annual Report on Form 10-K for the fiscal year ended December 31, 2010 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 11-15


CORPORATE CONTACT
David H. Fater
Vicor Technologies, Inc.
561.995.7313
dfater@vicortech.com

INVESTOR CONTACT
Richard Moyer
Cameron Associates
212.554.5466
richard@cameronassoc.com

MEDIA CONTACT
Robin Schoen
Robin Schoen Public Relations
215.504.2122
rschoen@robinschoenpr.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES